A Quantitative Model for Spontaneous Bone Metastasis: Evidence for a Mitogenic Effect of Bone on Walker 256 Cancer Cells

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 1992 Nov 1

PMID 1451350

Citations 8

Authors

P J Kostenuik

G Singh

K L Suyama

F W Orr

Affiliations

Soon will be listed here.

Abstract

A new model for the study of spontaneous bone metastasis has been developed which allows for the quantification of metastatic tumor burden and cancer cell growth rate, and which describes the progressive changes in bone morphology. Walker 256 (W256) cells or vehicle were injected into the left upper thigh muscle of male Fischer rats, which were killed 7, 10 or 14 days later. By day 7, metastases had appeared in the distal femur, in the glomeruli of the kidney, and diffusely throughout the liver and lungs. The extent of tumor burden in these organs increased over time. In the femur, 14 days of tumor burden was associated with a 53 +/- 10% decrease in trabecular bone content, a 61 +/- 15% increase in osteoclast surface, and a 95 +/- 10% decrease in osteoblast surface, as compared with non-tumor-bearing controls. By autoradiography, metastatic tumor cells in all organs were determined to have greater growth rates than did cells in the primary tumor. However, within the femur, W256 cells located adjacent to trabecular bone surfaces had a 33 +/- 7% greater growth rate than did W256 cells located > 50 microns from bone surfaces (P < 0.05), suggesting a mitogenic effect of bone.

Citing Articles

Osteoclast Signal Transduction During Bone Metastasis Formation.

Gyori D, Mocsai A Front Cell Dev Biol. 2020; 8:507.

PMID: 32637413 PMC: 7317091. DOI: 10.3389/fcell.2020.00507.

Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.

Steger G, Bartsch R Ther Adv Med Oncol. 2011; 3(5):233-43.

PMID: 21957430 PMC: 3169928. DOI: 10.1177/1758834011412656.

Breast Cancer: Rank Ligand Inhibition.

Bartsch R, Steger G, Gnant M, Ziebermayr R Breast Care (Basel). 2011; 5(5):320-325.

PMID: 21779214 PMC: 3132956. DOI: 10.1159/000321122.

Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications.

Terpos E, Dimopoulos M Cancer Immunol Immunother. 2011; 60(3):305-17.

PMID: 21243489 PMC: 11028766. DOI: 10.1007/s00262-011-0974-x.

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Kearns A, Khosla S, Kostenuik P Endocr Rev. 2007; 29(2):155-92.

PMID: 18057140 PMC: 2528846. DOI: 10.1210/er.2007-0014.

References

Turpeenniemi-Hujanen T, Thorgeirsson U, Hart I, Grant S, Liotta L . Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst. 1985; 75(1):99-103. View

Nicolson G . Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev. 1988; 7(2):143-88. DOI: 10.1007/BF00046483. View

Elte J, BIJVOET O, Cleton F, Van Oosterom A, Sleeboom H . Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol. 1986; 22(4):493-500. DOI: 10.1016/0277-5379(86)90117-3. View

Guaitani A, Polentarutti N, Filippeschi S, Marmonti L, Corti F, Italia C . Effects of disodium etidronate in murine tumor models. Eur J Cancer Clin Oncol. 1984; 20(5):685-93. DOI: 10.1016/0277-5379(84)90017-8. View

Schmidt-Gayk H, Lohrke H, Fischkal A, Goerttler K, Hofmann F . Urinary cyclic AMP and bone histology in Walker carcinosarcoma: evidence of parathyroid hormone-like activity. Eur J Cancer (1965). 1979; 15(10):1211-8. DOI: 10.1016/0014-2964(79)90246-9. View

Mundy G, Demartino S, Rowe D . Collagen and collagen-derived fragments are chemotactic for tumor cells. J Clin Invest. 1981; 68(4):1102-5. PMC: 370899. DOI: 10.1172/jci110334. View

Minne H, Raue F, Bellwinkel S, Ziegler R . The hypercalcaemic syndrome in rats bearing the Walker carcinosarcoma 256. Acta Endocrinol (Copenh). 1975; 78(3):613-24. DOI: 10.1530/acta.0.0780613. View

Sargent N, Oestreicher M, Haidvogl H, Madnick H, Burger M . Growth regulation of cancer metastases by their host organ. Proc Natl Acad Sci U S A. 1988; 85(19):7251-5. PMC: 282163. DOI: 10.1073/pnas.85.19.7251. View

Rayner D, Orr F, Shiu R . Binding of formyl peptides to Walker 256 carcinosarcoma cells and the chemotactic response of these cells. Cancer Res. 1985; 45(5):2288-93. View

10.

Simpkins H, Lehman J, Mazurkiewicz J, Davis B . A morphological and phenotypic analysis of Walker 256 cells. Cancer Res. 1991; 51(4):1334-8. View

11.

Bassani D, Sabatini M, Scanziani E, De Francesco L, Coccioli G, Guaitani A . Bone invasion by Walker 256 carcinoma, line A in young and adult rats: effects of etidronate. Oncology. 1990; 47(2):160-5. DOI: 10.1159/000226810. View

12.

WEISS L, Haydock K, PICKREN J, Lane W . Organ vascularity and metastatic frequency. Am J Pathol. 1980; 101(1):101-13. PMC: 1903569. View

13.

Orr F, Singh G . In vitro effects of bone- and platelet-derived transforming growth factor-beta on the growth of Walker 256 carcinosarcoma cells. Clin Exp Metastasis. 1990; 8(6):503-10. DOI: 10.1007/BF00135873. View

14.

Orr W, Varani J, Gondex M, Ward P, Mundy G . Chemotactic responses of tumor cells to products of resorbing bone. Science. 1979; 203(4376):176-9. DOI: 10.1126/science.569363. View

15.

Nicolson G, Dulski K . Organ specificity of metastatic tumor colonization is related to organ-selective growth properties of malignant cells. Int J Cancer. 1986; 38(2):289-94. DOI: 10.1002/ijc.2910380221. View

16.

Nemoto R . New bone formation and cancer implants; relationship to tumour proliferative activity. Br J Cancer. 1991; 63(3):348-50. PMC: 1971865. DOI: 10.1038/bjc.1991.83. View

17.

Powles T, Clark S, Easty D, EASTY G, Neville A . The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer. 1973; 28(4):316-21. PMC: 2008894. DOI: 10.1038/bjc.1973.154. View

18.

Orr F, Varani J, Gondek M, Ward P, Mundy G . Partial characterization of a bone-derived chemotactic factor for tumor cells. Am J Pathol. 1980; 99(1):43-52. PMC: 1903471. View

19.

Perrotti D, Cimino L, Falcioni R, Tibursi G, Gentileschi M, Sacchi A . Metastatic phenotype: growth factor dependence and integrin expression. Anticancer Res. 1990; 10(6):1587-97. View

20.

Orr F, Singh G . Chemotactic activity of bone and platelet-derived TGF-beta for bone-metastasizing rat Walker 256 carcinosarcoma cells. Invasion Metastasis. 1990; 10(4):241-52. View